Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $345,330.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 7,674 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $45.00, for a total value of $345,330.00. Following the sale, the director now owns 310,978 shares of the company’s stock, valued at $13,994,010. This trade represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Pro-Dex Trading Down 1.8 %

Shares of NASDAQ PDEX opened at $45.70 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The stock has a market capitalization of $149.03 million, a P/E ratio of 22.74 and a beta of 0.68. Pro-Dex, Inc. has a 1-year low of $16.83 and a 1-year high of $59.60. The business has a fifty day moving average price of $39.92 and a 200 day moving average price of $37.87.

Pro-Dex (NASDAQ:PDEX) last announced its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Equities research analysts expect that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com cut Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp acquired a new position in Pro-Dex during the 4th quarter valued at about $313,000. Millennium Management LLC acquired a new position in Pro-Dex during the 4th quarter valued at about $260,000. 683 Capital Management LLC acquired a new position in shares of Pro-Dex in the fourth quarter valued at about $739,000. Northern Trust Corp increased its holdings in shares of Pro-Dex by 14.1% in the fourth quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after purchasing an additional 4,426 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Pro-Dex in the fourth quarter valued at about $433,000. 15.28% of the stock is owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.